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ABSTRACT
Delirium has been associated with a high risk of mortality in medical patients. Despite the high incidence of
delirium in patients who undergo hemapoietic stem cell transplantation (HSCT), delirium as a risk factor for
death has not been examined in this population. Thirty adult patients undergoing HSCT who were admitted
to the University of Iowa Blood and Marrow Transplantation Program inpatient unit were assessed prospec-
tively from 1 to 2 weeks before transplantation, throughout their inpatient stay, and at 100 days after
transplantation. The Delirium Rating Scale and Memorial Delirium Assessment Scale were used twice weekly
during the inpatient period to assess delirium severity and occurence. Patients’ self-reports of medical history,
computerized medical records, and neuropsychological and psychiatric assessments were used to identify
pretransplantation risk factors. The incidence of delirium (Delirium Rating Scale score >12 or Memorial
Delirium Assessment Scale score >8) was 43% and occurred with highest frequency in the first 2 weeks after
transplantion. The presence of delirium at any point during hospitalization after transplantation and transplant
type (allogeneic) were highly predictive of mortality (p < .0005; odds ratios, 14.0 and 14.4). In conclusion, this
study highlights the importance of monitoring for delirium during the acute recovery period after transplan-
tation and suggests that early or even prophylactic treatment for delirium should be studied. Studies to
determine the factors that connect delerium soon after transplantation to mortality are highly warranted.
© 2006 American Society for Blood and Marrow Transplantation
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Delirium is a common medical morbidity in can-
er patients, with up to 40% experiencing this alter-
tion in consciousness [1]. The incidence is as high as
5% in patients with additional medical burden, such
s late-stage and terminal cancers [2]. Unfortunately,
elirium is poorly recognized in cancer patients, with
s many as 66% undiagnosed [2,3]. Poor detection is
robably exacerbated by the common presentation of
ypoactive delirium in cancer patients, which is less
ikely to draw attention from the treatment team and
amily [4]. Early detection and proper treatment of
elirium is critical because delirium has been associ-
ted with a signiﬁcantly increased risk of mortality
3,5] and a host of other negative outcomes (eg, longer
ospital stay, poorer long-term outcome) [6,7]. i
28Previous research has identiﬁed risk factors asso-
iated with delirium in medical patients, including
dvanced age, cognitive impairment, illness, opioid
se, and undergoing medical procedures [1,4,7-9]. In a
eries of the only published studies examining delir-
um in patients undergoing hemapoietic stem cell
ransplantation (HSCT), Fann and colleagues [6,10]
eported very high rates of delirium (73%) in patients
uring the 4 weeks after HSCT. In those studies,
elirium was predicted by poorer cognitive perfor-
ance and metabolic abnormalities (serum urea nitro-
en [BUN]) at baseline before transplantation.
Predictors of major complications and mortality in
atients undergoing HSCT have been examined in
everal studies and multiple risk factors have been
dentiﬁed. Although the exact mechanisms of treat-
m
f
t
p
m
p
a
o
b
p
t
m
f
A
v
H
e
p
p
c
t
t
w
s
e
i
m
H
I
M
P
a
w
t
a
b
P
p
b
a
t
f
t
i
t
a
t
t
c
P
p
a
g
c
t
f
(
w
t
i
d
s
i
w
ﬁ
p
t
b
c
f
c
w
o
t
p
s
M
m
t
e
d
a
o
d
m
h
h
c
(
a
l
c
u
S
M
g
T
t
t
p
a
f
i
Delirium in HSCT Patients 929ent-related mortality and interrelations among risk
actors are not fully understood, there is agreement
hat mortality is multifactorial [11]. Older age of the
atient, HLA mismatch, intensive treatment regi-
ens, total body irradiation, graft-versus-host disease
rophylaxis, and allogeneic transplant type have been
ssociated with poor outcome [11-13]. Metabolic lab-
ratory variables, such as BUN and bilirubin levels
efore [13] or soon after [14] transplantation, have
redicted mortality months to years after transplanta-
ion. In addition, unrelated donor status predicted
ortality, but at a much weaker level. Robin et al [15]
ound pretransplantation and late bacterial infections,
BO blood group incompatibility, and chronic graft-
ersus-host disease to predict mortality. Recently,
ahn and colleagues [11] found high-intensity my-
loablative therapy to predict mortality in allogeneic
atients. Despite the high incidence of delirium in
atients who undergo HSCT and the serious compli-
ations associated with delirium in medical patients,
here are no reports of delirium associated mortality in
his population. We sought to replicate and extend the
ork of Fann and colleagues [6] by prospectively as-
essing the incidence of delirium after HSCT and
xamining a set of a priori deﬁned predictors of delir-
um from the literature and the associated risk for
ortality in 30 adult patients at the University of Iowa
olden Comprehensive Cancer Center (Iowa City,
owa).
ETHODS
atients
Patients were from the University of Iowa Blood
nd Marrow Transplantation Program (BMTP) and
ere approached for participation in the study upon
heir admission to the BMTP inpatient unit for an
llogeneic or autologous bone marrow or peripheral
lood HSCT from 2004 to 2005.
rocedures
The protocol and all study procedures were ap-
roved by the University of Iowa institutional review
oard. All patients provided written informed consent
nd were ﬁnancially compensated for their participa-
ion in the study. Patients were assessed prospectively
rom before transplantation through 100 days after
ransplantation. In addition, patients are currently be-
ng followed for 1-year follow-up data. During a pre-
ransplantation appointment, when patients were
mbulatory and before beginning their pretransplan-
ation preparative conditioning (eg, chemotherapy),
hey were approached by a BMTP nurse research
oordinator and invited to participate in the study.
articipants were contacted to set up the pretrans-
lantation (baseline) assessment. During the baseline mssessment, a comprehensive battery assessing demo-
raphic and medical information, cognitive and psy-
hiatric functioning, and delirium was administered to
he patients. Additional demographic and medical in-
ormation was obtained from computerized records
eg, laboratory values including BUN, creatinine, and
hite blood cell count). At 5 days after transplanta-
ion, patients began a twice-per-week assessment reg-
men consisting of a brief cognitive functioning and
elirium assessment battery. This twice-per-week as-
essment schedule continued for the duration of the
npatient stay until 28 days after transplantation or
hen the patient was discharged, whichever occurred
rst. Patients were assessed at 100 days after trans-
lantation with the same cognitive and affective func-
ioning and delirium assessment battery used at the
aseline assessment. All but 3 patients had been dis-
harged and were tested as outpatients at the 100-day
ollow-up. BMTP staff were notiﬁed if patients’ psy-
hiatric functioning levels at the baseline assessment
ere elevated. In addition, if staff noticed symptoms
f delirium during a nonassessment day, the research
eam was notiﬁed and a visit was scheduled as soon as
ossible. This resulted identifying 6 additional epi-
odes of delirium.
easurements
Medical history and status. Patients’ general and
edical backgrounds were assessed by using a struc-
ured clinical interview. The clinical interview gath-
red the following information: demographics (age,
ate of birth, education, handedness, weight, current
nd previous employment, and marital status); history
f diagnosis (including speciﬁc diagnosis and date of
iagnosis); previous treatment (including date and
edications/procedures); other signiﬁcant medical
istory (eg, heart attack); family history (eg, cancer,
eart disease); cognitive history (current cognitive
omplaints and time of onset); psychiatric history
current complaints and time of onset); and history of
lcohol, drug, and/or tobacco use or abuse.
Cognitive functioning. The following neuropsycho-
ogical tests were administered to assess the areas of
ognition most prone to dysfunction in patients who
nderwent HSCT. (1) The Modiﬁed Mini-Mental
tate Examination is an expanded version of the Mini-
ental State Examination, with 100 points to assess
lobal cognitive functioning [16]. (2) Trailmaking
est Parts A and B [17] are widely used standardized
ests of psychomotor speed, attention, and set shifting
hat have been shown to be predictive of delirium in
atients undergoing HSCT [6] and have strong reli-
bility and validity [18]. (3) The Repeatable Battery
or the Assessment of Neuropsychological Status [19]
s a brief, individually administered battery of tests
easuring attention, language, visuospatial/construc-
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L. J. Beglinger et al930ional abilities, and immediate and delayed memories.
4) The Wechsler Abbreviated Scale of Intelligence
20] provides an estimate of full-scale IQ based on 2
ubtests (Vocabulary and Matrix Reasoning). (5) A
isual analog scale of thinking clarity consists of a
00-mm straight line with verbal descriptors and im-
ges at each end. The verbal descriptors are short
hrases describing the variable being measured (eg,
clear thinking”/“trouble with thinking”). The patient
raws a line to represent cognition at the time of
ssessment.
Psychiatric assessment. The Symptom Checklist-90-
evised [21] is a 90-item self-report symptom inven-
ory designed to reﬂect patterns of current psycholog-
cal symptoms. Each item is rated on a 5-point scale,
rom “not at all” to “extremely.” The measure yields 3
lobal indices of distress (Global Severity Index, Pos-
tive Symptom Total, and Positive Symptom Distress
ndex) and 9 primary symptom dimensions (Somati-
ation, Obsessive-Compulsive, Interpersonal Sensitiv-
ty, Depression, Anxiety, Hostility, Phobic Anxiety,
aranoid Ideation, and Psychoticism). Normative data
re available for gender and patient status (inpatient,
utpatient, nonpatient) that results in T scores, which
ave a mean of 50 (SD, 10). Visual analog scales of
ain and mood were also administered.
Delirium assessment. The Delirium Rating Scale
DRS) [22] is a 10-item clinician rating scale of delir-
um severity based on all available information from
atient interview, family, and nurses’ reports, cogni-
ive tests, and medical reports measured over a 24-
our period. The maximum possible score is 32, with
igher scores being more indicative of delirium. A
RS score 12 was used as a cutoff for delirium.
The Memorial Delirium Assessment Scale
MDAS) [23] is a 10-item clinician rating scale of
elirium presence and severity and can be adminis-
ered multiple times in 1 day. The MDAS has been
alidated against many commonly used delirium as-
essment measurements [24] and in patient popula-
ions with malignant disease [25]. Items on the MDAS
ange from 0 to 3, depending on severity and fre-
uency. A MDAS score 8 was used as a cutoff for
elirium, with higher scores being more indicative of
elirium.
tatistical Analyses
Patients were coded as having delirium if they
xceeded the cutoff value on the DRS or MDAS at any
oint after transplantation. Univariate logistic regres-
ion was used to predict which patients experienced
elirium from cognitive, psychiatric, and medical lab-
ratory variables at baseline. Due to a small absolute
umber of deaths, exact logistic regression [26] was
onducted to examine predictors of mortality. wESULTS
atient Characteristics
Thirty-two patients who were admitted to the
niversity of Iowa BMTP for HSCT consented to
articipate in the study. Two patients who completed
he baseline assessment did not proceed to a HSCT
nd therefore did not complete testing after transplan-
ation. These patients were excluded from the analy-
es. The remaining 30 patients completed 2 to 8
cute-phase assessments after transplantation (mean,
.8; SD, 1.7). At the time of assessment 100 days after
ransplantation, 6 patients were deceased and 1 de-
lined to participate. One additional patient died at
ay 369 after transplantation and was included in the
nalysis.
An equal number of patients received autologous
n  15) and allogeneic (n  15) transplants. Most
atients had lymphomas or leukemias (67%). Patients
ho underwent an autologous HSCT received high-
ose, multiagent chemotherapy for myeloablative
herapy. Allogeneic HSCT patients received mostly
otal body irradiation and high-dose chemotherapy or
usulfan-based high-dose chemotherapy. One patient
reviously underwent allogeneic HSCT and 1 patient
reviously underwent autologous HSCT. Patient
haracteristics are listed in Table 1.
escriptive Delirium Results
The number of patients who exceeded the cutoff
or delirium on either scale at any point during the
cute phase after transplantation was 13, or a cumu-
ative incidence of 43%. The highest prevalence of
elirium was at visit 3 (28%), or approximately 12 days
fter transplantation. As shown in Figure 1, delirium
ccurred most frequently in the ﬁrst and second weeks
fter HSCT. The average duration of delirium was 2.8
ays (SD, 2.9; range, 1-9). All patients had only 1
eriod of delirium while in the hospital followed by a
ormal sensorium, and once delirium resolved, they
id not experience another discrete delirium. How-
ver, 1 patient had a second delirium episode imme-
iately before his death 2 months later. The mean
cores on the DRS and MDAS in patients who did and
id not have delirium are reported in Table 2.
Baseline risk factors for delirium were examined
ith univariate logistic regression. The following pre-
ransplantation variables were signiﬁcant predictors:
hite blood cell count, hematocrit, and platelet count
all P  .05). No demographic, neuropsychological,
sychiatric, or delirium measurements at baseline sig-
iﬁcantly predicted delirium acutely after transplanta-
ion.
ortality Risk Factors
The total rate of mortality during the study period
as 23% (7 patients deceased by 1-year follow-up).
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Delirium in HSCT Patients 931he average number of days between onset of delir-
um and death was 114.8  130 (range, 1-369); delir-
um occurred 55 days before death in all but 1
atient. Regression analyses described below were
ompleted with and without this participant and re-
ults were very similar, except that odds ratios and P
alues were slightly lower, but the interpretation re-
ained the same. Our primary analysis examined the
ollowing variables in exact logistic regression as pre-
ictors of mortality: delirium (present or absent),
ransplant type (autologous versus allogeneic), my-
loablative therapy (present or absent), and age. As a
econdary, exploratory analysis, the following vari-
able 1. Demographic Characteristics of Patients Undergoing Hematop
or Delirium Risk
Demographics n Range
D
(n
ge (y) 30 21-64 45.
ducation (y) 30 11-24 15.
ex
Male 20
Female 10
iagnosis (vs other)
Leukemia 7
Lymphoma 13
Myeloma 6
Other 4
onor type
Autologous 15
Allogeneic 15
tem cell type
Bone marrow 14
Peripheral blood 16
yeloablative
Yes 26
No 4
S indicates not signiﬁcant.
Mean  SD or number of patients.
For diagnosis type, the test for signiﬁcant differences across all type
odds ratio estimates differ slightly from what would be obtaine
showed signiﬁcant differences only between the “other” group a
median unbiased estimated odds ratios are presented. For p
comparisons are deleted.
igure 1. Percentage of patients exceeding the threshold for delir-
um (DRS score12 or MDAS score8) at baseline (solid bar) and
uring the 4 weeks after HSCT (gray bars represent visits occurringtwice weekly after HSCT beginning on day 5 after transplantation).bles were also examined as possible predictors of
ortality: creatinine, BUN, baseline cognition (Re-
eatable Battery for the Assessment of Neuropsycho-
ogical Status total score), IQ, age, Trail Making Test
art B, and mental status (Modiﬁed Mini-Mental
tate Examination). Only delirium (P  .03) and
ransplant type (P .01) were signiﬁcant predictors of
ortality. The odds ratios were 14.0 for delirium and
4.4 for transplant type. The classiﬁcation table is
hown in Table 3 and yielded on overall accuracy of
0.0%. When controlling for age and myeloablative
herapy, delirium and transplant type remained signif-
cant as listed above, but the odds ratios were lowered
o 4.2 (delirium) and 8.6 (transplant type). The regres-
ion was also run to control for each of the 3 labora-
ory values that predicted delirium (Table 2). Al-
hough controlling for hematocrit did not appreciably
ower the delirium odds ratio (12.5), controlling for
latelets or white blood cells did decrease the delirium
dds ratios to 3.0 and 5.6, respectively. Delirium was
o longer statistically signiﬁcant in either of these
odels. The loss of statistical signiﬁcance can be ex-
lained by the predictive inﬂuence of these hemato-
ogic variables on the development of delirium (see
bove.) At the same time, the continued elevation of
he estimated odds ratio suggests a unique contribu-
tem Cell Transplantation (n  30 Patients) and Univariate Regression
*
No
Delirium*
Odds Ratio P(n  17)
.3 49.1  11.7 0.75 NS
14.6  2.7 1.08 NS
13 — NS
4 2.79 NS
<.05†
3 0.35
9 0.11
5 0.09
0 8.93
NS
10
7 2.29
NS
7 1.67
10
NS
14 2.57
3
igniﬁcant at P  .03 by exact logistic regression. (The concomitant
the usual observed data calculation.) Follow-up pairwise analyses
homa and myeloma. In light of 100% delirium in the other group,
y, the (nonsigniﬁcant) estimated odds ratios of other pairwiseoietic S
elirium
 13)
7  10
5  4.2
7
6
4
4
1
4
5
8
7
6
12
1
s was s
d from
nd lymp
arsimonion from delirium to mortality. The deaths in the
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L. J. Beglinger et al932ample were too few to disentangle the relative inﬂu-
nce of delirium and these delirium predictors with
ny statistical power.
ISCUSSION
In the present sample of adult patients undergoing
SCT, the incidence of delirium was 43% and oc-
urred most frequently in the ﬁrst and second weeks
fter transplantation. This study addresses an impor-
ant and previously unanswered question in this pop-
able 2. Clinical, Neuropsychological, and Psychiatric Pretransplantatio
Variable Range Patients With D
etabolic
BUN 8-36 17.8  9.
Creatinine 0.6-1.1 0.82  0.
Alkaline phosphatase 35-356 66.6  19
Bilirubin 0.2-4.8 0.95  1.
ematologic
White blood cells 0.1-56.4 3.3  3.
Hematocrit 21-44 28.5  5.
Platelets 6-294 81.6  63
lectrolytes
Sodium 133-144 138.1  2.
Potassium 3.3-5.1 4.0  0.
Magnesium 1.5-2.2 1.9  0.
Calcium 7.2-9.6 8.2  0.
Phosphorous 2.0-4.4 3.5  0.
europsychological
3MS total 81-100 94.1  5.
RBANS total 57-121 90.9  12
Trails A Z score 4.8 to 1.42 0.5  1.
Trails B Z score 9.3 to 1.3 1.9  2.
WASI FSIQ 67-128 103.6  16
sychiatric
SCL-90-R
Global severity 35-80 60.2  13
Depression 38-80 63.2  12
Anxiety 37-80 59.1  11
Pain rating 0-84 20.0  27
elirium scales
DRS 1-7 4.2  1.
MDAS 0-8 3.1  2.
UN indicates serum urea nitrogen; 3MS, Modiﬁed Mini-Menta
Neuropsychological Status; Trails A Z, Trailmaking Test Part A
Wechsler Abbreviated Scale of Intelligence Full-Scale IQ; SC
MDAS, Memorial Delirium Assessment Scale.
Mean  SD.
Odds ratios are reported per SD change in predictor variable unl
able 3. Logistic Regression Classiﬁcation Table of Risk Factors for
ortality*
Actual Death
Predicted Death
No Yes
o 21 2
es 1 6
Model accuracy is 90.0%. Overall model was signiﬁcant at P 
m.0005 (delirium, P  .03; transplant type, P  .01).lation by examining whether delirium predicts mor-
ality. The presence of delirium and allogeneic
ransplantation strongly predicted mortality, with
dds ratios of 14 and 14.4, respectively. These are
arge odds ratios, thus underscoring the importance of
ecognizing delirium immediately after transplanta-
ion. Further, although white blood cell and platelet
ounts were clearly associated with delirium, there is
o strong evidence that these laboratory values before
ransplantation fully explain the relation between de-
irium and death. These are important open questions
hat can not be answered with this small dataset.
Transplantation-related mortality has been asso-
iated with several factors in previous research, in-
luding poor performance status before transplanta-
ion, active tumor at transplantation, high-dose
yeloablative therapy, mismatched donor, allogeneic
ransplantation, and graft-versus-host disease. The
resent study adds to the literature by providing evi-
ence of a strong association between delirium and
Factors for Delirium
* Patients Without Delirium* Odds Ratio† P
15.2  4.5 3.93 NS
0.88  0.15 0.2 NS
165.8  101.3 0.02 NS
0.47  0.22 >99.9 NS
14.7  18.3 0.13 .04
34.1  5.7 0.36 .03
145.0  82.0 0.34 .02
139.6  3.0 0.54 NS
3.9  0.2 1.68 NS
1.9  0.2 1.34 NS
8.9  0.9 0.16 NS
3.5  0.6 0.9 NS
93.7  4.7 1.02 NS
93.7  20.6 0.99 NS
1.2  1.6 1.42 NS
1.6  2.2 0.95 NS
106.8  13.6 0.99 NS
57.4  9.9 1.02 NS
60.8  9.6 1.02 NS
56.9  10.8 1.02 NS
13.8  20.6 1.01 NS
3.5  1.9 1.24 NS
2.3  1.9 1.19 NS
Examination; RBANS, Repeatable Battery for the Assessment of
s B Z, Trailmaking Test Part B; NS, not signiﬁcant; WASI FSIQ,
, Symptom Checklist-90-Revised; DRS, Delirium Rating Scale;
erwise indicated (based on the SD of our pooled total sample).n Risk
elirium
0
14
.9
24
7
3
.0
5
5
2
8
8
3
.8
2
7
.1
.2
.7
.1
.7
8
4
l State
; Trail
L-90-Rortality in patients who undergo HSCT. This link is
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Delirium in HSCT Patients 933ell established in other patient populations and is
ikely multifactorial [5]. The present study has several
trengths, including the several risk factors examined
ased on the previous literature and the prospective
tudy design. There were similarities and differences
egarding predictors of transplantation-related mor-
ality. Similar to other studies, we found allogeneic
ype transplantation to be a risk factor for mortality,
ut other risk factors such as age and cognitive status
id not predict death. Our results did not support the
ndings by Hahn and coworkers [11] that myeloabla-
ive therapy is related to mortality. However, our
ample is smaller and most of our patients received
yeloablative conditioning.
Although delirium is clearly associated with mor-
ality, it does not explain the underlying mechanism
nd is better conceptualized as an overall marker of
ysfunction (ie, a “sick” brain). In cancer patients,
elirium has been described as an “indirect effect”
esulting from infection, metabolic abnormalities (or-
an failure, electrolyte imbalance), hematologic com-
lications, medication and treatment effects (opioids,
hemotherapy, radiation), and general factors such as
educed nutrition, dehydration, and poor oxygenation
1,4,27]. In medical patients, delirium is associated
ith cholinergic dysfunction and often treated with
ntipsychotics that indirectly increase acetylcholine
4]. (For a review of possible mechanisms of delirium
elated to cholinergic deﬁciency, see Kalisvaart et al
28].) The central mechanism is an alteration in ace-
ylcholine modulation, which could result from ab-
ormal oxygenation or nutrition. An imbalance of
opamine or norepinephrine compared with acetyl-
holine is also postulated to cause multisystem dys-
unction.
The observations that delirium onset in our pa-
ients preceded death by 55 days in all but 1 patient
in that patient delirium was 1 day before death) and
hat markers of organ dysfunction measured at baseline
ere signiﬁcant predictors of delirium support the
otential for early identiﬁcation of the underlying
roblem and possible treatment. Alternatively, the in-
ensity of therapy that is required to control the pa-
ient’s malignancy before transplantation might ad-
ersely affect not only bilirubin and albumin levels but
lso other critical organ system functions. This would
lace a subset of patients at increased risk for delirium
nd at disadvantage for surviving transplantation.
hus, delirium may be in some way an early surrogate
arker of intolerance of the organism to the ultimate
umulative stress of transplantation. In future research
ith larger samples, an assessment of the causes of
eath may reveal what speciﬁc monitoring should be
one or what interventions might be important. The
nding that delirium occurred within the ﬁrst or sec-
nd week of transplantation and preceded death by a gumber of weeks certainly provides time to identify
nd correct medical factors that might be implicated.
Our ﬁnding of 43% delirium incidence is lower
han the 73% described by Fann et al [6] in 2002.
lthough the exact explanation for this discrepancy is
nknown, changes in conditioning regimens and
reatment improvements in the 5 years since their data
ere collected may be responsible for our lower rates
f delirium. Nevertheless, these rates of delirium are
otable when compared with those in other vulnerable
opulations, such as the elderly (10%) [29], medical
atients (20%-30%) [9,28], and cancer patients (40%)
1]. With regard to the timing of delirium, results
etween our study and theirs are remarkably consis-
ent, with the 2 studies ﬁnding the highest prevalence
t week 2 after transplantation. The converging re-
ults of these 2 studies underscore the importance of
onitoring for delirium immediately after transplan-
ation because nearly 50% of patients are likely to
evelop at least mild symptoms. The emerging evi-
ence of the reliability of the timing of delirium may
lso inform preventative treatment efforts similar to
hose in elderly surgical patients before they undergo
he procedure [28].
The timing of delirium in patients after HSCT
ay shed light on the underlying mechanism. For
xample, 2 weeks after transplantation is a common
ime during which patients are neutropenic and may
xperience fever and sepsis, which can cause delirium.
n addition, other clinical variables associated with
SCT are likely to be etiologically related to delir-
um, such as use of opioid pain medications, medica-
ions for nausea, medications for infusion and antibi-
tics, disease refractoriness, and pretransplantation
actors such as type and amount of chemotherapy and
ranial irradiation. Delirium-associated risk of death
ay be context speciﬁc. For example, delirium sec-
ndary to infection is quite plausibly a greater risk
actor than delirium secondary to anticholinergic
edication. Alternatively, delirium, regardless of ex-
cerbating circumstance, may represent the expression
f an underlying central nervous system fragility,
hich is a risk factor for mortality regardless of con-
ext. Unfortunately, our sample of 13 patients with
elirium is too small to address this question in a
eaningful way. In either case, the present research
nderscores the importance of recognizing delirium as
n empirical risk factor for poor outcome. Future
esearch with larger samples is urgently needed to
larify the contextual issues outlined above.
From a monitoring perspective, it is important to
ote that there are subtypes of delirium. Levkoff and
olleagues [30] described the traditional hyperactive
elirium in addition to a hypoactive and mixed delir-
um. Interestingly, the highest rate of mortality in
ospitalized patients was found in the hypoactive
roup. Fann and Sullivan [4] described the importance
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L. J. Beglinger et al934f monitoring for hypoactive delirium, which is more
ommon in cancer patients. Recently, Fann et al. [10]
escribed the presentation of delirium from their ini-
ial sample collected between 1997 and 1999. In ad-
ition to the traditional symptoms necessary for diag-
osis, the most common symptoms were sleep-wake
ycle disturbance, psychomotor disturbance, and cog-
itive impairment. Nearly all patients with delirium
ad psychomotor alteration and 86% were hypoactive.
hey also found that fatigue, depression, and anxiety
ere strongly related to delirium and argued that
hese symptoms may also alert staff to delirium in
atients with fewer typical overt symptoms. Further,
ecause any form of delirium, but particularly hypo-
ctive delirium, has been associated with cognitive
mpairments in the areas of attention and memory,
taff and families need to be aware of the reduced
apacity of patients to fully understand and consider
reatment and research options. Decreased decisional
apacity may not be obvious in a patient with hypo-
ctive delirium. Further research is needed to evaluate
atients’ ability to provide appropriate consent in the
rst few weeks after transplantation.
Some limitations of the present study should be
oted. The participants in the present sample had
eterogeneous diagnoses and conditioning regimens.
t will be important in future studies to examine the
ncidence of delirium and mortality in speciﬁc diag-
ostic subgroups. Our sample was also relatively
mall, and these results should be considered prelim-
nary and need to be replicated. Several intriguing
rends may become signiﬁcant with a larger sample.
or example, female gender, myeloablative therapy,
nd allogeneic transplantation had odds ratios 2.5 as
redictors of delirium, but none were statistically sig-
iﬁcant due to limited power. Similarly, many of the
linical variables mentioned above (eg, fever, sepsis)
re likely related in a causal way to delirium and, as
oted earlier, the interplay between these obvious risk
actors and delirium needs to be studied. Moreover,
he generalizability of these ﬁndings may be limited to
igh functioning groups because our average patient
as highly educated (2-3 years of college) and may
ave had greater cognitive reserve.
In conclusion, these results highlight the impor-
ance of monitoring for delirium in patients after
SCT, particularly in the ﬁrst and second weeks after
ransplantation. Nursing staff and others with fre-
uent patient contact are particularly well suited to
etect delirium early in its course and should be aware
f the high incidence immediately after transplanta-
ion and the atypical presentation of delirium symp-
oms (ie, fatigue, sleep cycle disturbance, reduced cog-
ition and affect). Future research examining the
linical factors underlying delirium and whether med-
cal intervention for delirium may decrease mortality
re of critical importance.CKNOWLEDGMENTS
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